Abiopharma

Phibro Animal Health Corporation Declares Quarterly Dividend

Revolution Medicines to Participate in November 2025 Investor Conferences

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Standard BioTools Reports Third Quarter 2025 Financial Results

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Sight Sciences to Present at Two Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences